Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Other Operating Expenses (2017 - 2025)

Neurocrine Biosciences' Other Operating Expenses history spans 15 years, with the latest figure at $34.6 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 181.3% year-over-year to $34.6 million; the TTM value through Dec 2025 reached $554.5 million, up 42.54%, while the annual FY2025 figure was $69.5 million, 49.46% up from the prior year.
  • Other Operating Expenses reached $34.6 million in Q4 2025 per NBIX's latest filing, up from $14.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $265.0 million in Q1 2025 to a low of $2.9 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $77.9 million, with a median of $24.4 million recorded in 2025.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 3500.0% in 2021, then tumbled 93.33% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at $104.4 million in 2021, then plummeted by 92.62% to $7.7 million in 2022, then grew by 10.39% to $8.5 million in 2023, then surged by 44.71% to $12.3 million in 2024, then soared by 181.3% to $34.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Operating Expenses are $34.6 million (Q4 2025), $14.3 million (Q3 2025), and $240.6 million (Q2 2025).